Particles

ABSTRACT

Embolic particles are described. The particles are reaction products of a prepolymer solution including at least one polyether macromer and an appropriate monomer.

CROSS REFERENCE TO RELATED APPLICATIONS

This application is a continuation of U.S. patent application Ser. No.15/878,294, filed Jan. 23, 2018, which is a continuation of U.S. patentapplication Ser. No. 15/081,648, filed Mar. 25, 2016, now U.S. Pat. No.9,907,880, which claims the benefit of U.S. provisional patentapplication No. 62/138,859, filed Mar. 26, 2015, the entire disclosureseach of which are incorporated herein by reference.

FIELD

The present invention relates to embolic particles that have a firstdiameter that can fit through a microcatheter or other delivery deviceand a second expanded diameter once implanted.

SUMMARY

Described herein generally are embolic particles. These embolicparticles can be used for medical purposes such as occluding vasculardefects. In some embodiments, the embolic particles described herein canbe used to occlude other luminal defects such as those in the bileducts, urethra, vagina, fallopian tubes, and the like. Embolic particlescan include a treated polymer particle containing ionic groups.

The treated polymer particles can have a smaller first diameter whendelivered and then swell or otherwise enlarge to a larger seconddiameter once a certain condition has been met. The condition can besubjecting the treated embolic particles to a physiological condition.

The embolic particles can have a first diameter of between about 40 μmand about 1,200 μm and can enlarge to the second diameter of about 80 μmand about 3,600 μm.

In order to allow the embolic particles to occlude vascular defects,larger particles are desired. However, smaller particles allow deliverythrough smaller microcatheters. A smaller microcatheter is particularlyadvantageous in tortuous and/or distal anatomy. Thus, the first diameterdescribed can be smaller than the inner diameter of a microcatheter andthe second diameter can be larger than the inner diameter of themicrocatheter.

Methods of making and using the polymer particles are also described. Inone embodiment, methods of making polymer particles comprise treatingpolymer particles to render them expandible at a certain condition(s).The polymer particles can be formed by reacting a monomer solutionincluding at least one monomer or macromer, an monomer including ionicgroups, optionally a crosslinker, and initiator(s) in a non-solvent toform polymer particles which can be subsequently treated. In someembodiments, the treated polymer particle has a first diameter and asecond diameter wherein the second diameter is larger than the firstdiameter when the treated polymer particle is subjected to aphysiological condition.

In one embodiment, the non-solvent is a mineral oil. In anotherembodiment, the non-solvent is hexane. In another embodiment thenon-solvent is water.

In another embodiment, the at least one monomer is any moleculecontaining a single ethylenic unsaturation. In some embodiments, themonomer is acrylamide. In some embodiments, the monomer ismethacrylamide. In some embodiments, the monomer is hydroxyethylmethacrylate.

In another embodiment, the at least one macromer is a polyether such asa derivatized polyether. In some embodiments the polyether macromer is apoly(ethylene glycol) macromer. The derivatized poly(ethylene glycol)macromer can be poly(ethylene glycol) diacrylamide, poly(ethyleneglycol) diacrylate, poly(ethylene glycol) dimethacrylate, poly(ethyleneglycol) dimethacrylamide, or a combination thereof. In some embodiments,the at least one derivatized poly(ethylene glycol) macromer ispoly(ethylene glycol) diacrylamide 10,000.

In another embodiment, the optional crosslinker is any moleculecontaining a multiplicity of ethylenic unsaturations. In someembodiments, the at least one macromer can function as the crosslinker.In some embodiments, the crosslinker is N,N-methylene bisacrylamide. Inother embodiments, the crosslinker is ethylene glycol dimethacrylate. Inother embodiments, the crosslinker is glyercerol dimethacrylate.

In some embodiments, the physiological condition can be a conditionfound in the blood or other bodily fluid such as urine, bile, saliva,vaginal fluids, and the like. In one embodiment, the physiological pH ofthe blood or other bodily fluid is the condition.

In some embodiments, the treated polymer particle is an acid treatedpolymer particle. When the treated polymer particle is an acid treatedpolymer particle, the particle contains carboxylic acid groups.Likewise, in other embodiments, the treated polymer particle is a basetreated polymer particle. When the treated polymer particle is a basetreated polymer particle, the particle contains amino groups.

If an initiator is utilized, the initiator can be ammonium persulfate,tetramethylethylene diamine, or a combination thereof. In otherembodiments, heat sensitive initiators such as azobisisobutyronitrile(AIBN) or a water soluble AIBN derivative is utilized.

DETAILED DESCRIPTION

Described herein generally are devices and methods for occludingvascular or other luminal defects. Devices as used herein can describeembolics and embolic devices generally. In one embodiment, an embolicdevice can be embolic particles.

Embolic particles can be generally sphere-shaped or a particle-shaped“bead” or “microsphere” made of a biocompatible substance. The embolicparticles can be injected through a microcatheter.

Embolic particles as described herein can be delivered to a vasculardefect or other lumen by various delivery methods. In one embodiment, amethod can start by accessing the aneurysm with a catheter ormicrocatheter. A flow diverting stent (FDS) is then deployed across theneck of the aneurysm. The flow diverting stent allows the microcatheterto be “jailed” in place. After the microcatheter has been jailed, one ormore embolic devices such as, but not limited to beads, foams,particles, or other agents can be delivered through the microcatheter.These embolic devices are physically larger than the maximum pore sizeof the flow diverting stent. The microcatheter is then removed therebytrapping the embolics within the aneurysm behind the flow divertingstent.

In one embodiment, the embolic particles can be sized to be small enoughto travel through a microcatheter without clogging or occluding themircocatheter, yet large enough so that the particles do not migratethrough the flow diverting stent's mesh structure.

In one embodiment, the embolic particles can be small enough to fitthrough a microcatheter. The microcatheter can have a size of at mostabout 0.0155″, at most about 0.0160″, at most about 0.0165″, at mostabout 0.0170″, at most about 0.0175″, at most about 0.018″, at mostabout 0.019″, or at most about 0.02″. In one embodiment, themicrocatheter can be a 0.0165″ (about 420 microns) microcatheter. Inanother embodiment, a microcatheter can be a Headway Duo.

Also, in one embodiment, the embolic particles can be large enough, orhave a large enough average diameter, that they do not migrate through aparticular sized mesh. In some embodiments, the mesh can be a meshopening of a flow diverting stent. The embolic particles describedherein, unlike conventional particles can have diameters large enough tobe delivered using such a mesh.

In some embodiments, the mesh of a flow diverting stent can include amesh opening of about 0.006″ (about 150 microns). In other embodiments,the mesh size can be at most about 0.04″, at most about 0.05″, at mostabout 0.06″, at most about 0.07″, at most about 0.08″, or at most about0.09″. In some embodiments, the flow diverting stent can be a flowre-direction endoluminal device, referred to by the tradename FRED®(MicroVention, Inc. Tustin, Calif.).

In one embodiment, the size range for the embolic is about 200 micronsto about 500 microns.

In other embodiments, in order maximize the size of the embolicparticles, the embolic particles can be expansible. In such embodiments,the embolic particles can start at a smaller diameter so that they canbe delivered through a smaller microcatheter and then expand at thephysiological site to provide maximum volumetric filling.

In one embodiment, for example, the embolic particles can have aninitial diameter of about 200 microns to about 500 microns and, afterdeployment, can expand to about 400 microns to about 1500 microns.

Expansible embolic particles deliverable through a smaller microcathetercan have a number of advantages. First, a smaller microcatheter iseasier to navigate through tortuous anatomy, particularly to distallocations. Second, a smaller microcatheter can be used in conjunctionwith standard flow diverting stent delivery systems (for example, theHeadway 27 or Headway 21) in a standard 6F guide catheter, thus avoidingthe need to increase the guide catheter size or making a second punctureon the contralateral side, saving the patient from additional injury orpotential access site complications. Third, a smaller microcatheter mayensure a tighter seal and smaller opening where the microcatheter isjailed by the flow diverting stent thus reducing the possibility ofmigration of the embolic during delivery.

The embolic particles described herein may be formed of any materialthat can expand once delivered to an occlusion site such as a vasculardefect. The expansile embolic particles can be any particle containingionic groups that are pretreated with the appropriate low or high pHsolutions to shrink the diameter of the particle.

The embolic particles can be formed by reacting a monomer or prepolymersolution including (i) at least one monomer or macromer, (ii) an monomerincluding ionic groups, (iii) optionally a crosslinker, and (iv)initiator(s) in a non-solvent to form polymer particles which can besubsequently treated. The embolic particles can also be formed from amonomer or prepolymer solution or mixture comprising: (i) one or moremacromer(s), for example, a macromer that contains at least twofunctional groups amenable to polymerization, (ii) one or more ionicmonomers, and (iii) optionally one or more multifunctional crosslinkers.In some embodiments, a polymerization initiator may be utilized.

In one embodiment, the particle embolics can comprise (i) one or moremonomers that contain both a singular functional group amenable topolymerization and ionizable groups and (ii) one or more monomeric ormacromeric crosslinkers.

In one embodiment, expansile embolic particles can include variouscombinations of macromers and optionally monomers. For example, one,two, three or more macromers can be included in the embolic particles.Further, one, two, three or more monomers can be included in the embolicparticles.

In one embodiment, the macromer can include a plurality of functionalgroups suitable or amenable to polymerization. In some embodiments, themacromer can be linear. In other embodiments, the macromer can have oneor more branches. In still other embodiments, the macromer can be anethylenically unsaturated macromer. Macromers can include polyethers.Polyether macromers can include linear or branched poly(ethyleneglycol), poly(propylene glycol), poly(tetramethylene oxide), derivativesthereof, or combinations thereof. Macromers can also include linear orbranched poly(vinyl alcohol).

Macromers described herein can have molecular weights of about 200grams/mole, 400 grams/mole, 600 grams/mole, 800 grams/mole, 1,000grams/mole, 2,000 grams/mole, 3,000 grams/mole, 4,000 grams/mole, 5,000grams/mole, 10,000 grams/mole, 15,000 grams/mole, 20,000 grams/mole,25,000 grams/mole, 30,000 grams/mole, 35,000 grams/mole, between about200 grams/mole and about 35,000 grams/mole, between about 200 grams/moleand about 30,000 grams/mole, between about 200 grams/mole and about1,000 grams/mole, between about 1,000 grams/mole and about 15,000grams/mole, at least about 200 grams/mole, at most about 30,000 g/mole,or at most about 35,000 grams/mole. In one embodiment, macromers canhave a molecular weight of about 10,000 g/mole.

When used as a crosslinker, a macromer can have a low molecular weightof about 200 grams/mole, 400 grams/mole, 600 grams/mole, 800 grams/mole,1,000 grams/mole, or between about 200 grams/mole and about 1,000grams/mole.

Derivatives of these polyethers can be prepared to render them amenableto polymerization. While any type of chemistry can be utilized, forexample nucleophile/N-hydroxysuccinimde esters, nucleophile/halide,vinyl sulfone/acrylate or maleimide/acrylate; another type of chemistrycan be free radical polymerization. As such, polyethers with a pluralityof ethylenically unsaturated groups, such as acrylate, acrylamide,methacrylate, methacrylamide, and vinyl, can be used. In one embodiment,a polyether macromer can be poly(ethylene glycol) diacrylamide with amolecular weight of about 10,000 g/mole.

In another embodiment the macromer is poly(ethylene glycol)diacrylamide, poly(ethylene glycol) diacrylate, poly(ethylene glycol)dimethacrylate, poly(ethylene glycol) dimethacrylamide, derivativesthereof, or combinations thereof.

Macromers can be included at a concentration in the solvent of about 0%w/w, about 1% w/w, about 2% w/w, about 3% w/w, about 4% w/w, about 5%w/w, about 6% w/w, about 7% w/w, about 8% w/w, about 9% w/w, about 10%w/w, about 11% w/w, about 12% w/w, about 13% w/w, about 14% w/w, about15% w/w, about 16% w/w, about 17% w/w, about 18% w/w, about 19% w/w,about 20% w/w, about 25% w/w, about 30% w/w, about 35% w/w, about 40%w/w, about 45% w/w, about 50% w/w, about 60% w/w, about 70% w/w, betweenabout 5% w/w and about 10% w/w, between about 5% w/w and about 20% w/w,between about 5% w/w and about 25% w/w, between about 5% w/w and about15% w/w, between about 6% w/w and about 8% w/w, or between about 14% w/wand about 16% w/w. In some embodiments, a macromer need not be used.

In one embodiment, the macromer can be included at a concentration ofabout 7% w/w in the solvent.

In one embodiment, the macromer can be included at a concentration ofabout 15% w/w in the solvent.

In one embodiment, the macromer can be included at a concentration ofabout 16.5% w/w in the solvent.

In one embodiment, the macromer can be included at a concentration ofabout 17% w/w in the solvent.

In some embodiments, if one of the monomer(s) and/or macromers(s) is asolid, a solvent can be utilized in the preparation of the particles foruse as embolics. If liquid monomers and macromers are utilized, asolvent may not be required. In some embodiments, even when using liquidmonomers and/or macromers, a solvent may still be used. Solvents mayinclude any liquid that can dissolve or substantially dissolve amacromer, monomers, multifunctional crosslinkers, and/or initiators. Anyaqueous or organic solvent may be used that dissolves the desiredmonomer(s), macromer(s), multifunctional crosslinker(s) and/orpolymerization initiators. In one embodiment, the solvent can be water.In another embodiment, the solvent can be dimethyl formamide.Additionally, solutes, e.g. sodium chloride, may be added to the solventto increase the rate of polymerization. Solvent concentration can bevaried to alter the swelling properties of the particles.

Solvent concentrations can be about 25% w/w, about 35% w/w, about 45%w/w, about 55% w/w, about 65% w/w, about 75% w/w, about 85% w/w, about95% w/w, between about 40% w/w and about 80% w/w, between about 30% w/wand about 90% w/w, or between about 50% w/w and about 70% w/w of thesolution. In one embodiment, the solvent concentration can be about 50%w/w, about 51% w/w, about 52% w/w, about 53% w/w, about 54% w/w, about55% w/w, about 56% w/w, about 57% w/w, about 58% w/w, about 59% w/w, orabout 60% w/w. In another embodiment, the solvent concentration can beabout 65% w/w, about 66% w/w, about 67% w/w, about 68% w/w, about 69%w/w, about 70% w/w, about 71% w/w, about 72% w/w, about 73% w/w, about74% w/w, or about 75% w/w. In some embodiments, the concentration of thesolvent ranges from about 20% w/w to about 80% w/w or about 50% w/w toabout 60% w/w.

In one embodiment, the solvent concentration can be about 57% w/w.

In one embodiment, the solvent concentration can be about 70% w/w.

In one embodiment, the solvent concentration can be about 71.6% w/w.

In one embodiment, the solvent concentration can be about 72% w/w.

In general, monomers can contain moieties such as acrylate, acrylamide,methacrylate, methacrylamide or other moieties amenable topolymerization. In one embodiment, the polymer particles are comprisedof one or more macromers combined with one or more monomers.

Optionally, one or more monomers can be added to the macromer to impartdesired chemical and/or mechanical properties to the polymer particle.

To reduce the diameter and to allow control of the rate of expansion ofthe embolic particles, monomers with ionic moieties, e.g. carboxylicacids and amines, can be polymerized into the particle embolic. In someembodiments, monomer(s) can be acidic and ethylenically unsaturated.Such monomers can include acrylic acid, methacrylic acid, 3-sulfopropylacrylate, 3-sulfopropyl methacrylate, derivatives thereof, combinationsthereof, and salts thereof. Preferred basic, ionizable, ethylenicallyunsaturated monomers include aminoethyl methacrylate, aminopropylmethacrylate, derivatives thereof, combinations thereof, and saltsthereof.

Monomers including positive or negative moieties can be present insolution at concentrations of about 0.5% w/w, about 1% w/w, about 2%w/w, about 3% w/w, about 4% w/w, about 5% w/w, about 6% w/w, about 7%w/w, about 8% w/w, about 9% w/w, about 10% w/w, about 15% w/w, about 20%w/w, about 21% w/w, about 22% w/w, about 23% w/w, about 24% w/w, about25% w/w, about 26% w/w, about 27% w/w, about 28% w/w, about 29% w/w,about 30% w/w, about 40% w/w, about 50% w/w, about 55% w/w, about 60%w/w, about 65% w/w, about 70% w/w, about 80% w/w, between about 1% w/wand about 15% w/w, between about 1% w/w and about 5% w/w, between about15% w/w and about 35% w/w, or between about 20% w/w and about 30% w/w.In other embodiments, monomers can be present in the solvent at a rangeof between about 40% w/w and about 60% w/w.

In one embodiment, sodium acrylate can be included at a concentration ofabout 12% w/w in the solvent.

In one embodiment, N-(2-aminoethyl)-methacrylate can be included at aconcentration of about 3% w/w in the solvent.

In one embodiment, N-(3-aminopropyl) methacrylamide can be included at aconcentration of about 24% w/w in the solvent.

In one embodiment, the monomer is not n-isopropyl acrylamide. In otherembodiments, the polymer particles described herein do not includen-isopropyl acrylamide.

If desired, uncharged, reactive moieties can be introduced into theparticles. For example, hydroxyl groups can be introduced into theparticles with the addition of 2-hydroxyethyl acrylate, 2-hydroxyethylmethacrylate, glycerol monomethacrylate, glycerol monoacrylate, sorbitolmonomethacrylate, sorbitol monoacrylate, a carbohydrate similar tosorbitol and amenable to polymerization, derivatives thereof, orcombinations thereof. Alternatively, uncharged, relatively un-reactivemoieties can be introduced into the particles. For example, acrylamide,methacrylamide, methyl methacrylate, derivatives thereof, orcombinations thereof can be added to the polyether macromer. In someembodiments, the monomer(s) can be selected to vary the number ofhydroxyl groups in the polymeric particles to enable the particles toremain suspended in radiopaque contrast solution used in the preparationof the particle for clinical use.

Further, in other embodiments, monomers may be selected to impartvisualization using medically relevant imaging techniques. Visualizationof the embolic particles under fluoroscopy can be imparted by theincorporation of solid particles of radiopaque materials such as barium,bismuth, tantalum, platinum, gold, and other dense metals into thehydrogel or by the incorporation of iodine-containing moleculespolymerized into the embolic structure. In one embodiment, visualizationagents for fluoroscopy are barium sulfate and iodine-containingmolecules. Visualization of the embolic particles under computedtomography imaging can be imparted by incorporation of solid particlesof barium or bismuth or by the incorporation of iodine-containingmolecules polymerized into the embolic structure. Metals visible underfluoroscopy generally result in beam hardening artifacts that precludethe usefulness of computed tomography imaging for medical purposes. Insome embodiments, visualization agents for fluoroscopy are bariumsulfate or iodine-containing molecules. Concentrations of barium sulfateto render the embolic particles visible using fluoroscopic and computedtomography imaging can range from about 30% to about 60% w/w in thesolvent of the prepolymer solution. Concentrations of iodine to renderthe embolic particles visible using fluoroscopic and computed tomographyimaging can range from about 80 to about 300 mg l/g of particles in thesolvent of the prepolymer solution.

Visualization of the embolic particles under magnetic resonance imagingcan be imparted by the incorporation of solid particles ofsuperparamagnetic iron oxide or gadolinium molecules polymerized intothe embolic structure. In one embodiment, a visualization agent formagnetic resonance can be superparamagnetic iron oxide with a particlesize of 10 microns. Concentrations of superparamagnetic iron oxideparticles to render the embolic particles visible using magneticresonance imaging range from 0.1% to 1% w/w in the solvent of theprepolymer solution.

In some embodiments, a visualization agent can be a monomer andincorporated into the polymeric structure.

Monomers incorporating visualization characteristics can include one ormore halogen atoms. For example, monomers can include 1, 2, 3, 4, 5, 6,7 or more halogen atoms. In some embodiments, the halogen atoms can beBr or I. In one embodiment, the halogen atoms are I.

In one embodiment, a monomer including a visualization agent or thecharacteristics of a visualization agent can have a structure:

In the above structure, one or more iodine atoms can be replaced bybromine.

In another embodiment, a monomer including a visualization agent or thecharacteristics of a visualization agent can have a structure:

Again, in the above structure, one or more iodine atoms can be replacedby bromine.

In another embodiment, a monomer including a visualization agent or thecharacteristics of a visualization agent can have a structure:

Again, in the above structure, one or more iodine atoms can be replacedby bromine.

Such uncharged moieties if included can be present in the final particle(not including solvents, initiators, and salts) at about 0% w/w, about10% w/w, about 20% w/w, about 30% w/w, about 40% w/w, about 50% w/w,about 60% w/w, about 61% w/w, about 62% w/w, about 63% w/w, about 64%w/w, about 65% w/w, about 66% w/w, about 67% w/w, about 68% w/w, about69% w/w, about 70% w/w, about 71% w/w, about 72% w/w, about 73% w/w,about 74% w/w, about 75% w/w, about 80% w/w, about 90% w/w, betweenabout 50% w/w and about 90% w/w, between about 60% w/w and about 70%w/w, between about 65% w/w and about 70% w/w, or between about 67% w/wand about 69% w/w.

In one embodiment, an uncharged moiety can be present at about 68% w/wof the final particle.

In one embodiment, multifunctional crosslinkers may be incorporated thatcontain at least two functional groups suitable to polymerization and atleast one linkage susceptible to breakage under physiological conditionsto impart biodegradation to the polymer particle. Linkages susceptibleto breakage in a physiological environment include those susceptible tohydrolysis, including esters, thioesters, carbamates, oxalates, andcarbonates, and those susceptible to enzymatic action, includingpeptides that are cleaved by matrix metalloproteinases, collagenases,elastases, and cathepsins. Multiple crosslinkers could be utilized tocontrol the rate of degradation in a manner that is not possible withonly one.

Crosslinkers described herein include a plurality of polymerizablegroups and can join monomers and macromers together thereby permittingthe formation of solid embolic particles. Biodegradation can be impartedto the embolic particles by utilizing a crosslinker with linkagessusceptible to degradation in a physiological environment. Over time, invivo the linkages can break thereby unbinding the polymer chains. Thejudicious selection of monomers permits the formation of water-solubledegradation products that diffuse away and are cleared by the host.Linkages susceptible to hydrolysis, such as esters, thioesters,carbamates, oxalates, and carbonates, or peptides degraded by enzymesare preferred methods of imparting biodegradation to the embolicparticles.

Adding multifunctional crosslinkers containing more than one moietyamenable to polymerization can create a more cohesive hydrogel polymerby adding crosslinking to the molecular structure. In some embodimentsthe polymer particles are comprised of a macromer combined with one ormore multifunctional crosslinkers such as, but not limited to, glyceroldimethacrylate, glycerol diacrylate, sorbitol dimethacrylate, sorbitolacrylate, a derivatized carbohydrate similar to sorbitol, derivativesthereof, or combinations thereof. In a preferred embodiment themultifunctional crosslinker is N,N′-methylenebisacrylamide.

In one embodiment, a biodegradable crosslinker can have a structure:

wherein each n is independently 1-20.

In one embodiment, a biodegradable crosslinker can have a structure:

In another embodiment, a biodegradable crosslinker can have a structure:

wherein d, e, f, and g are each independently 1-20.

In another embodiment, a biodegradable crosslinker can have a structure:

If used, a crosslinker can be present in amount of about 0.1% w/w, about0.25% w/w, about 0.5% w/w, about 0.75% w/w, about 1.0% w/w, about 1.25%w/w, about 1.5% w/w, about 1.75% w/w, about 2% w/w, about 3% w/w, about4% w/w, about 5% w/w, about 6% w/w, about 7% w/w, about 10% w/w, about20% w/w, about 25% w/w, about 30% w/w, between about 0% w/w and about10% w/w, between about 0% w/w and about 2% w/w, between about 0.5% w/wand about 1.5% w/w, between about 0.25% w/w and about 1.75% w/w, orbetween about 0.1% w/w and about 2% w/w.

In one embodiment, a crosslinker is not used.

In one embodiment, a crosslinker can be present at about 1% w/w.

In one embodiment, the crosslinker can be N,N′-methylenebisacrylamide.

Any amounts of macromer(s), monomer(s), and multifunctionalcrosslinker(s) can be used that allows for a desired particle. Totalconcentration of reactive compounds or solids in the solvent can beabout 5% w/w, about 10% w/w, about 11% w/w, about 12% w/w, about 13%w/w, about 14% w/w, about 15% w/w, about 16% w/w, about 17% w/w, about18% w/w, about 19% w/w, about 20% w/w, about 21% w/w, about 22% w/w,about 23% w/w, about 24% w/w, about 25% w/w, about 30% w/w, about 31%w/w, about 32% w/w, about 33% w/w, about 34% w/w, about 35% w/w, about36% w/w, about 37% w/w, about 38% w/w, about 39% w/w, 40% w/w, about 50%w/w, about 60% w/w, about 70% w/w, between about 10% and 60%, betweenabout 15% w/w and about 50% w/w, or between about 20% w/w and about 40%w/w.

In one embodiment, the total concentration of reactive compounds in thesolvent can be about 20% w/w.

In one embodiment, the total concentration of reactive compounds in thesolvent can be about 28% w/w.

In one embodiment, the total concentration of reactive compounds in thesolvent can be about 37% w/w.

In one embodiment, polymer embolic particles can be prepared frommonomers having a single functional group and/or macromers having two ormore functional groups suitable for polymerization. Functional groupscan include those suitable to free radical polymerization, such asacrylate, acrylamide, methacrylate, vinyl, and methacrylamide. Otherpolymerization schemes can include, but are not limited tonucleophile/N-hydroxysuccinimide esters, nucleophile/halide, vinylsulfone/acrylate or maleimide/acrylate. Selection of the monomers isgoverned by the desired chemical and mechanical properties of theresulting particle.

The prepolymer solution or components in the appropriate solvent can bepolymerized by reduction-oxidation, radiation, heat, or any other methodknown in the art. Radiation cross-linking of the prepolymer solution canbe achieved with ultraviolet light or visible light with suitableinitiators or ionizing radiation (e.g. electron beam or gamma ray)without initiators. Cross-linking can be achieved by application ofheat, either by conventionally heating the solution using a heat sourcesuch as a heating well, or by application of infrared light to themonomer solution. In some embodiments, free radical polymerization ofthe polymerizable components requires an initiator to start thereaction. In one embodiment, the cross-linking method utilizesazobisisobutyronitrile (AIBN) or another water soluble AIBN derivative(2,2′-azobis(2-methylpropionamidine) dihydrochloride). Othercross-linking agents useful according to the present description includeN,N,N′,N′-tetramethylethylenediamine, ammonium persulfate, benzoylperoxides, and combinations thereof, including azobisisobutyronitriles.In yet another embodiment the initiator is the combination ofN,N,N′,N′-tetramethylethylenediamine and ammonium persulfate at aconcentration of 5% w/w and 1.8% w/w or 10% w/w and 2.5% w/w,respectively.

In one embodiment, the prepolymer solution can be prepared by dissolvingmacromer(s), monomer(s), crosslinker(s), and initiator(s) in thesolvent. The embolic particles can be prepared by emulsionpolymerization in some embodiments. A non-solvent for the prepolymersolution, typically mineral oil when the monomer solvent is water, maybe sonicated or sparged with inert gas to remove any entrapped oxygen.The mineral oil and a surfactant can be added to the reaction vessel. Anoverhead stirrer is placed in the reaction vessel. The reaction vesselis then sealed, degassed under vacuum, and sparged with argon. Theinitiator component, such as in one non-limiting embodimentN,N,N′,N′-tetramethylethylenediamine, is added to the reaction vesseland stirring commenced. Ammonium persulfate can be added to thepolymerization solution and both are then added to the reaction vessel,where the stirring suspends droplets of the polymerization solution inthe mineral oil.

The rate of stirring can affect the size of the resulting embolicparticles. In some embodiments, faster stirring can produce smallerparticles and slower stirring can produce larger particles. Stirringrates can be about 100 rpm, about 200 rpm, about 300 rpm, about 400 rpm,about 500 rpm, about 600 rpm, about 700 rpm, about 800 rpm, about 900rpm, about 1,000 rpm, about 1,100 rpm, about 1,200 rpm, about 1,300 rpm,between about 200 rpm and about 1,200 rpm, between about 400 rpm andabout 1,000 rpm, at least about 100 rpm, at least about 200 rpm, at mostabout 250 rpm, at most about 500 rpm, at most about 1,000 rpm, at mostabout 1,300 rpm, or at most about 1,200 rpm to produce particles withdesired diameters. In one embodiment, stirring rates can range from 200to 1,200 rpm to produce particles with diameters ranging from 10 to1,500 microns.

Polymerization can be allowed to proceed as long as necessary to produceparticles. Polymerization can be allowed to proceed for about 1 hr, 2hrs, 2.5 hrs, 3 hrs, 4 hrs, 5 hrs, 6 hrs, 7 hrs, 8 hrs, 9 hrs, 10 hrs,11 hrs, 12 hrs, 18 hrs, 24 hrs, 48 hrs, 72 hrs, 96 hrs, between about 1hr and about 12 hrs, between about 1 hr and about 6 hrs, between about 4hrs and about 12 hrs, between about 6 hrs and about 24 hrs, betweenabout 12 hrs and about 72 hrs, or at least about 6 hours.

Polymerization can be run at a temperature to produce embolic particleswith desired diameters. Polymerization can be run at a temperature ofabout 10° C., about 15° C., about 20° C., about 25° C., about 30° C.,about 35° C., about 40° C., about 45° C., about 50° C., about 60° C.,about 70° C., about 80° C., about 90° C., about 100° C., between about10° C. and about 100° C., between about 10° C. and about 30° C., atleast about 20° C., at most about 100° C., or at about room temperature.In one embodiment, polymerization occurs at room temperature.

After the polymerization is complete, the polymeric embolic particlescan be washed to remove any solute, mineral oil, unreacted monomer(s),unreacted crosslinker(s), unreacted macromer(s), and/or unboundoligomers. Any solvent may be utilized, but care should be taken ifaqueous solutions are used to wash particles with linkages susceptibleto hydrolysis. Preferred washing solutions include acetone, hexane,alcohols, water+surfactant, water, and saline. In another embodiment,the washing solution is a combination of hexane followed by water. Inanother embodiment, the washing solution is saline. In furtherembodiments, the washing solution is water and a surfactant.

Optionally, the washed embolic particles can then be dyed to permitvisualization before injection into a microcatheter. A dye bath can bemade by dissolving sodium carbonate and the desired dye in water.Embolic particles are added to the dye bath and stirred. After the dyingprocess, any unbound dye is removed through copious washing. After dyingand additional washing, the microspheres are packaged into vials orsyringes, and sterilized.

Dyes can include any of the dyes from the family of reactive dyes whichbond covalently to the embolic particles. Dyes can include reactive blue21, reactive orange 78, reactive yellow 15, reactive blue No. 19,reactive blue No. 4, C.I. reactive red 11, C.I. reactive yellow 86, C.I.reactive blue 163, C.I. reactive red 180, C.I. reactive black 5, C.I.reactive orange 78, C.I. reactive yellow 15, C.I. reactive blue No. 19,C.I. reactive blue 21, any of the color additives approved for use bythe FDA part 73, subpart D, or any dye that can irreversibly bond to thepolymer matrix of the embolic particles.

Desired treated polymer particle diameters can be about 10 μm, about 20μm, about 30 μm, about 40 μm, about 50 μm, about 100 μm, about 200 μm,about 300 μm, about 400 μm, about 500 μm, about 600 μm, about 700 μm,about 800 μm, about 900 μm, about 1,000 μm, about 1,100 μm, about 1,200μm, about 1,300 μm, about 1,400 μm, about 1,500 μm, about 1,600 μm,about 1,700 μm, about 1,800 μm, about 1,900 μm, about 2,000 μm, betweenabout 50 μm and about 1,500 μm, between about 100 μm and about 1,000 μm,at least about 50 μm, at least about 80 μm, less than about 600 μm, lessthan about 1,000 μm, less than about 1,200 μm, or less than about 1,500μm. In one embodiment, the diameter is less than about 1,200 μm.

Desired expanded polymer particle diameters can be about 80 μm, about100 μm, about 200 μm, about 400 μm, about 500 μm, about 600 μm, about700 μm, about 800 μm, about 900 μm, about 1,000 μm, about 1,100 μm,about 1,200 μm, about 1,300 μm, about 1,400 μm, about 1,500 μm, about1,600 μm, about 1,700 μm, about 1,800 μm, about 1,900 μm, about 2,000μm, about 2,100 μm, about 2,200 μm, about 2,300 μm, about 2,400 μm,about 2,500 μm, about 2,600 μm, about 2,700 μm, about 2,800 μm, about2,900 μm, about 3,000 μm, about 3,100 μm, about 3,200 μm, about 3,300μm, about 3,400 μm, about 3,500 μm, about 3,600 μm, about 3,700 μm,about 3,800 μm, about 3,900 μm, about 4,000 μm,between about 80 μm andabout 3,600 μm, between about 400 μm and about 4,000 μm, at least about400 μm, at least about 2,000 μm, less than about 3,000 μm, less thanabout 3,500 μm, less than about 4,000 μm, or less than about 3,700 μm.In one embodiment, the expanded polymer particle diameter is about 3,600μm.

In one embodiment, the concentration of macromer(s) in the final embolicparticle products can be about 58% w/w.

In one embodiment, poly(ethylene glycol) diacrylamide is present in thefinal embolic particle products at about 58% w/w.

In one embodiment, the crosslinker can be N,N′-methylenebisacrylamide.

In other embodiments, no crosslinker is included in the desiccatedembolic particle products.

In one embodiment, the concentration of one or more monomers in thefinal embolic particle products can be about 42% w/w.

In one embodiment, the one or more monomers can be sodium acrylate and2-amino ethyl methacrylate.

In one embodiment, the one or more monomers can be sodium acrylate.

A skilled artisan understands how to calculate final concentrationsbased on amount in solvent already discussed.

The embolic particles can then be treated to delay the rate at whichthey expand in a physiological environment. For embolic particlescontaining acidic moieties, incubation in acidic solution is performed.For embolic particles containing basic moieties, incubation in basicsolution is performed. Alternatively, incubation in sodium chloridesolutions with higher osmolarity than physiological may decrease thediameter of the embolic particles.

Another method is to formulate the embolic particles with ionicsensitivity. The embolic can be packaged in a concentrated salinesolution with a much higher salt concentration than the human body, thusshrinking the embolic. When delivered to the body, the osmotic balancewill be restored to the embolic particles as the concentrated salinesolution washes away by dilution from the blood. Thus, the embolicparticles become exposed to a lower ionic strength environment, causingthem to swell to a larger diameter.

A third method is to dehydrate the embolic particles and acid treat themso that they become responsive to physiologic pH. The embolic particlescan then be packaged in a low pH, aqueous solution, such as water, or anon-aqueous, biocompatible solution such as mineral oil, alcohol,poly(ethylene glycol) 400, dimethyl sulfoxide, or lipiodol for delivery.

A fourth method is to dehydrate the embolic particles and basic treatthem so that they become responsive to physiologic pH. The embolicparticles can then be packaged in a high pH, aqueous solution, such aswater, or a non-aqueous, biocompatible solution such as mineral oil,alcohol, poly(ethylene glycol) 400, dimethyl sulfoxide, or lipiodol fordelivery.

The final polymer embolic particle preparation is delivered to the siteto be embolized via a catheter or similar delivery device. In someembodiments, a radiopaque contrast agent is thoroughly mixed with theparticle preparation in a syringe and injected through a catheter untilblood flow is determined to be occluded from the site by interventionalimaging techniques.

The embolic particles described herein can be sterilized withoutsubstantially degrading the polymer. After sterilization, at least about50%, about 60%, about 70%, about 80%, about 90%, about 95% about 99% orabout 100% of the polymer can remain intact. In one embodiment, thesterilization method can be autoclaving and can be utilized beforeadministration.

The embolic particles can remain substantially stable once injected. Forexample, the polymer particles can remain greater than about 60%, about70% about 80%, about 90%, about 95%, about 99% or about 100% intactafter about 5 days, about 2 weeks, about 1 month, about 2 months, about6 months, about 9 months, about a year, about 2 years, about 5 years,about 10 years, or about 20 years.

The polymer particles described herein can be compressible yet durableenough not to break apart or fragment. Substantially no change incircularity or diameter of particles may occur during delivery through amicrocatheter. In other words, after delivery through a microcatheter,the polymer particles described herein remain greater than about 60%,about 70%, about 80%, about 90%, about 95%, about 99% or about 100%intact yet expand to a size larger than when delivered.

The embolic particles can be cohesive enough to stick to tissue and/orremain in place through friction with the tissue. In other embodiments,the particles can act as a plug in a vessel held in place by the flowand pressure of blood.

The embolic particles described herein can have a characteristicexpansion time and that characteristic expansion time can be predictableand/or predetermined. This characteristic expansion time can be theamount of time required for the embolic particles to expand from theirinitial or first diameter to their larger, second expanded diameter.This time can be about 5 min, about 10 min, about 15 min, about 20 min,about 25 min, about 30 min, between about 5 min and about 20 min,between about 10 min and about 25 min, between about 5 min and about 30min, at least about 5 min, or at least about 10 min.

Also, this characteristic expansion time can provide a user, for examplea physician, sufficient time to deliver the particles to the desired insitu location without the particles expanding and clogging amicrocatether or other deliver device.

In one embodiment, a desiccated polymeric embolic particle can include areaction product of a polyether and sodium acrylate. In anotherembodiment, a polymeric embolic particle can include a polyether atabout 58% w/w and sodium acrylate at about 42% w/w.

In another embodiment, a desiccated polymeric embolic particle caninclude a reaction product of a polyether, aminopropyl methacrylamide,and sulfopropyl acrylate. In another embodiment, a polymeric embolicparticle can include a polyether at about 40% w/w, aminopropylmethacrylamide at about 1% w/w, and sulfopropyl acrylate at about 59%w/w.

The following represent non-limiting embodiments.

Embodiment 1: An embolic composition comprising: embolic particlesincluding acidic groups that are treated with a low pH solution to formtreated embolic particles, wherein the treated embolic particles have afirst diameter and a second diameter, and wherein the second diameter islarger than the first diameter when the treated polymer particle issubjected to a physiological condition.

Embodiment 2: The embolic composition of Embodiment 1, wherein the firstdiameter is between about 40 μm and about 1,200 μm.

Embodiment 3: The embolic composition of Embodiment 1 or 2, wherein thefirst diameter is smaller than the diameter of a microcatheter.

Embodiment 4: The embolic composition of Embodiment 1, 2, or 3, whereinthe second diameter is between about 80 μm and about 3,600 μm.

Embodiment 5: The embolic composition of Embodiment 1, 2, 3, or 4,wherein the second diameter is larger than the diameter of themicrocatheter.

Embodiment 6: The embolic composition of Embodiment 1, 2, 3, 4, or 5,wherein the embolic particles include a reaction product of a prepolymersolution including at least one macromer and at least one monomerincluding ionic groups.

Embodiment 7: The embolic composition of Embodiment 1, 2, 3, 4, 5, or 6,wherein the monomer containing ionic groups is sodium acrylate.

Embodiment 8: The embolic composition of Embodiment 1, 2, 3, 4, 5, 6, or7, wherein the at least one macromer is poly(ethylene glycol)diacrylamide, poly(ethylene glycol) diacrylate, poly(ethylene glycol)dimethacrylate, poly(ethylene glycol) dimethacrylamide, or a combinationthereof.

Embodiment 9: The embolic composition of Embodiment 1, 2, 3, 4, 5, 6, 7,or 8, wherein the prepolymer solution further includes a biodegradablecrosslinker.

Embodiment 10: The embolic composition of Embodiment 9, wherein thebiodegradable crosslinker has a structure:

wherein each n is independently 1-20;

wherein d, e, f, and g are each independently 1-20; or

Embodiment 11: The embolic composition of Embodiment 1, 2, 3, 4, 5, 6,7, 8, or 9, wherein the embolic particles further include avisualization agent.

Embodiment 12: The embolic composition of Embodiment 11, wherein thevisulaization agent is an monomer including a visualization agent andhas a structure

Embodiment 13: The embolic composition of Embodiment 1, 2, 3, 4, 5, 6,7, 8, 9, 10, 11, or 12, wherein the physiological condition isphysiological pH.

Embodiment 14: A method of making polymer particles comprising: treatingpolymer particles formed by reacting a prepolymer solution including atleast one macromer, an acrylic monomer, and an initiator in non-solventto form treated polymer particles; wherein the treated polymer particlehas a first diameter and a second diameter, wherein the second diameteris larger than the first diameter when the treated polymer particle issubjected to a physiological condition.

Embodiment 15: The method of Embodiment 14, wherein the non-solvent is amineral oil, hexane, or water.

Embodiment 16: The method of Embodiment 14 or 15, wherein the initiatoris ammonium persulfate, tetramethylethylene diamine, or a combinationthereof.

Embodiment 17: The method of Embodiment 14, 15, or 16, wherein the firstdiameter is between about 40 μm and about 1,200 μm.

Embodiment 18: The method of Embodiment 14, 15, 16, or 17, wherein thefirst diameter is smaller than the diameter of a microcatheter.

Embodiment 19: The method of Embodiment 14, 15, 16, 17, or 18, whereinthe second diameter is between about 80 μm and about 3,600 μm.

Embodiment 20: The method of Embodiment 14, 15, 16, 17, 18, or 19,wherein the second diameter is larger than the diameter of themicrocatheter.

Embodiment 21: The method of Embodiment 14, 15, 16, 17, 18, 19, or 20,wherein the at least one macromer is poly(ethylene glycol) diacrylamide,poly(ethylene glycol) diacrylate, poly(ethylene glycol) dimethacrylate,poly(ethylene glycol) dimethacrylamide, or a combination thereof.

Embodiment 22: The method of Embodiment 14, 15, 16, 17, 18, 19, 20, or21, wherein the treating is acid treating and the monomer containingionic groups is sodium acrylate.

Embodiment 23: The method of Embodiment 14, wherein the treating is basetreating and the monomer containing ionic groups includes amino groups.

EXAMPLE 1 Biostable Embolic Particle Preparation

A prepolymer solution was prepared by dissolving 9.2 g poly(ethyleneglycol) 10,000 diacrylamide and 6.6 g sodium acrylate in 39.8 g ofdistilled water. This solution was filtered and flushed with argon.Then, 500 mL of mineral oil was sparged with argon for 6 hr in a sealedreaction vessel equipped with an overhead stirring element. N,N,N′,N′tetramethylethylenediamine (3 mL) was added to the reaction vessel andoverhead stirring started at 230 RPM. An initiator solution was made bydissolving 1.0 g ammonium persulfate in 2.0 g distilled water. Thesolution was filtered and 1 mL added to the prepolymer solution. Aftermixing, the solution was added to the reaction vessel. After 5 to 10min, 0.1 mL of SPAN®80 was added and the resulting suspension wasallowed to polymerize over 4 hrs.

EXAMPLE 2 Purification of the Embolic Particle Preparation

After the polymerization was complete, the mineral oil was decanted fromthe reaction vessel and the polymer embolic particles were washed fourtimes with fresh portions of hexane to remove the mineral oil. Theparticles were then transferred to a separatory funnel with phosphatebuffered saline (PBS) and separated from residual mineral oil andhexane. The resulting mixture was washed twice with PBS.

To dye the embolic particles, 50 g of sodium carbonate and 0.1 greactive black 5 dye (Sigma-Aldrich Co. LLC, St. Louis, Mo.) weredissolved in 1,000 mL of de-ionized water. Then, drained embolicparticles were added and allowed to stir for 1 hr. The dyed particlepreparation was washed with de-ionized water until all residual dye wasremoved.

The dyed embolic particles were separated in sizes using sieving. Sieveswere stacked from the largest size (on top) to the smallest size (onbottom). A sieve shaker was utilized to aid the sieving process. Theembolic particles were placed on the top sieve along with PBS. Once allthe embolic particles had been sorted, they were collected and placed inbottles according to their size.

Dyed particles were incubated in 0.1 N HCl for 30 minutes to protonateavailable carboxylic acid groups. Significant decrease in the diameterwas observed. The acid was removed and replaced with distilled water forstorage.

EXAMPLE 3 Preparation of a Biodegradable Crosslinker

Preparation of tetramesyl pentaerythritol (b): To a 3 L three-neck roundbottom flask fitted with a Dean-Stark trap was added pentaerythritol (a,MW˜797 g/mol, 99.9 g, 125 mmol) and toluene (1.5 L) sequentially. Thesolution was subjected to an azeotrope distillation and water wasremoved from the Dean-Stark trap. The flask was cooled to roomtemperature before triethylamine (94.6 mL, 530 mmol) was added. Then theflask was placed in a 0° C. ice bath. A 250 mL addition funnel wasattached to the flask. To the addition funnel was added anhydroustoluene (80 mL) and mesyl chloride (40 mL, 530 mmol) sequentially. Themesyl chloride solution was added dropwise to the cooled solution. Thereaction was left to stir at room temperature overnight, resulting inthe formation of a white precipitate. At the end of the reaction, thesolution was filtered over a fritted glass funnel to remove theprecipitate. The filtrate was concentrated using a rotary evaporator toafford the crude material as a pale yellow oil (86.37 g).

Preparation of tetraamino pentaerythritol (c): To a solution of ammoniumhydroxide (30%, 1250 mL, 22.02 mol) was added dropwise tetramesylpentaerythriol (b, 86.37 g, 77.8 mmol) in anhydrous acetonitrile (500mL). The reaction was stirred under room temperature for three days.Upon completion, it was degassed for 2 days using an air pump. Then thepH of the residue was adjusted to 14 using 0.1 M NaOH aqueous solution.The aqueous phase was extracted with dichloromethane (500 mL×1, and 1L×1). The organic phase was then dried over sodium sulfate andconcentrated using a rotary evaporator to afford the product as a paleyellow oil (56.31 g).

Preparation of NHS-activated (4-hydroxyphenylmethacrylamide) (e): To asolution of (4-hydroxyphenylmethacrylamide) (d, 10 g, 56.4 mmol) inanhydrous acetonitrile (39.5 mL) was added anhydrous pyridine (9.9 mL,113 mmol) and disuccinimidyl carbonate (36.1 g, 141 mmol) sequentially.The solution was stirred for 18 hours at room temperature. Uponcompletion, the reaction was poured over dichloromethane (40 mL) andfiltered over a Buchner funnel. The filtrate was collected and thesolvent was removed on a rotary evaporator. The residue was suspended in30 mL ethyl acetate. The ethyl acetate fraction was washed with 5%citric acid solution (30 mL×2) and saturated NaCl solution (30 mL×1)before being dried over Na₂SO₄. The solvent was removed on a rotaryevaporator to afford the product as a pinkish solid (12.96 g, 72.2%yield).

Preparation of a biodegradable crosslinker (f): To a solution oftetraamino pentaerythritol (c, 10.0 g, 12.6 mmol) and trimethylamine(7.0 mL, 50.4 mmol) in dichloromethane (67 mL) was added NHS-activated(4-hydroxyphenylmethacrylamide) (e, 16.0 g, 50.4 mmol) under argon. Thesolution was stirred for 3 hours 15 minutes. Upon completion, it waspassed through a silica gel plug. The elution was using a rotaryevaporator, and the residue was separated using flash chromatography toafford the product.

EXAMPLE 4 Preparation of a Biodegradable Crosslinker

To 10 g (67.6 1 mnol) of 2,2′-ethylenedioxy-bis-ethylamine was added 10g (70.4 mmol) of glycidyl methacrylate and 3.0 g of silica gel (Aldrich645524, 60 Angstrom 200-425 mesh), with good stirring. After stirringfor 1 hr, another 9 g (63.4 mmol) of glycidyl methacrylate was added andthe suspension was stirred for an additional 1.5 hr. The reactionmixture was diluted with 200 mL of reagent grade chloroform and filteredthrough a 600 mL fritted glass Buchner funnel of medium porosity, toremove silica gel. LC-MS analysis of the resultant chloroform solutionshowed almost no mono-glycidyl amino alcohol and mostly bis-glycidylamino alcohol at (M+H)⁺433 0.2 and was concentrated to about 50 g invacuo. The resultant heavy syrup was diluted to 100 mL with acetonitrileand stored at −80° C.

EXAMPLE 5 Preparation of a Biodegradable Crosslinker

TMP-Chloroacetamide (E): To 13.2 g of TMP amine in 250 mL of dry THF wasadded 6.32 g (80 mmols) of pyridine and this solution was added to 6.44g of chloroacetyl chloride in 250 mL of THF with good stirring, at 4-1°C. under Ar. After stirring for 15 min, the reaction mixture was warmedto room temperature and the THF and other volatile materials wereremoved in vacuo. The resulting solids were dissolved into 200 mL ofchloroform, washed with 100 mL of saturated aqueous sodium bicarbonate,dried over magnesium sulfate, and the solvent was removed in vacuo.

TMP-NH-Gly-Methacrylate (F): Approximately 15 grams of (E) was dissolvedinto 75 mL of anhydrous DMF and added 18 g of cesium methacrylate wasadded. The resulting suspension heated at 40-50° C. for 2 hr.

After precipitation with 500 mL of chloroform, the inorganic salts werecollected by filtration and the filtrate was concentrated to an oil invacuo to give 18 g of a reddish brown oil. This oil was polymerized withAIBN at 80° C., in isopropyl alcohol to a nice hard pellet.Chromatography on 6 g of this through a plug of the above silica with1,200 mL of 2-20% methanol in chloroform, gave 6 g of light red coloredmaterial. This material can be used to prepare polymer filaments.

The material can have a structure

wherein d, e, f, and g are each independently 1-20.

EXAMPLE 6 Preparation of a Biodegradable Crosslinker

To 653 mg (1 mmol) of tetrapeptide Alanine-Proline-Glycine-Leucine(APGL) in 5 mL dry DMF was added 190 mg (1.1 mmol) of APMA-HCl, followedby 174 μL (1 mmol) of DIPEA, at room temperature with good stirring,under Ar. After 2 hr, the reaction mixture was treated with 20 mg of BHTand briefly exposed to air. LC-MS analysis showed (M+H)⁺ at 680 and(M+Na)⁺ at 702. Then, 5 mL of the reaction mixture was added dropwise to200 mL of ether with good stirring and the solids which formed werecollected by centrifugation. The resulting pellet was dissolved into 20mL of (CHC1₃/MeOH/MeOH+5% aqueous ammonia) 90/5/5, and applied to 50 gof silica gel in a 5×20 cm column (Aldrich 645524, 60 Angstrom 200-425mesh). The silica gel column was developed with 500 mL of(CHC1₃/MeOH/MeOH with 5% aqueous ammonia), 90/5/5. The peptidecontaining eluent (TLC, same solvent) was concentrated in vacuo to yield110 mg of pale yellow oil, LCMS, as above. The pale yellow oil wasdissolved in 10 mL of methanol and stored at −80° C.

EXAMPLE 7 Preparation of a Degradable Radiopaque Monomer

Tetrabutylammonium diatrizoate: To a stirring suspension of diatrizoicacid (50 g, 81.4 mmol) in methanol (552 mL) was slowly addedtetrabutylammonium hydroxide (40% aqueous solution, 52.8 mL). The turbidsuspension turned clear after the addition of tetrabutylammoniumhydroxide was finished. The solvent was removed using a rotaryevaporator to obtain a cream-colored viscous residue. To this residuewas added an appropriate amount of toluene, which was then removed usinga rotary evaporator. Toluene was added to the residue once more andremoved again. The solid obtained was dried in a vacuum oven overnightat 40° C. to afford a white solid (64.1 g, 92% yield). (WO 95/19186)

Diatrizoyl HEMA: To a stirring solution of KI (796.8 mg, 4.38 mmol) and2-chloro ethylmethacrylate (4.32 mL, 32.1 mmol) in anhydrous DMF (122.6mL) was added tetrabutylammonium diatrizoate (25 g, 29.2 mmol) underargon. The flask was then placed in a 60° C. oil bath. Additional KI(199 mg) and 2-chloro ethylmethacrylate (1 mL) was added to the reactionat 13 hours, 38 hours and 41 hours reaction times. The reaction waspulled out of the oil bath at 44 hours and cooled under roomtemperature. The reaction was poured over saturated NaHCO₃ aqueoussolution (120 mL) and a white precipitate formed. The aqueous phase wasextracted once with a mixture of ethyl acetate (280 mL) and methanol (50mL). The organic phase was washed with saturated sodium chloride aqueoussolution (300 mL×1). The organic phase was subjected to rotaryevaporation to obtain a cream-colored wet solid. The solid was suspendedin a mixture of methyl tent-butyl ether and chloroform (7:3, v/v), andthe resulting suspension was filtered to obtain a white solid. The soliddried under reduced pressure to obtain the first crop of product as awhite solid (11.898 g). The previous NaHCO₃ phase was filtered and awhite solid was collected. The solid was washed with a mixture of methyltert-butyl ether and chloroform (7:3, v/v) and dried under reducedpressure to afford the second crop (3.071 g). The first and second cropswere combined to afford the final product as a white solid (14.969 g,70.6% yield).

EXAMPLE 8 Preparation of a Degradable Radiopaque Monomer

To 400 mL of methanol was added 104 g (170 mmol) of diatrizoic acidfollowed by 28 g of cesium carbonate (65 mmol). After stirring for 45min the methanol was removed in vacuo and the solids suspended in 500 mLof diethyl ether. The solids were then collected and dried on a Buchnerfunnel and further dried in vacuo, to yield 120 g, (95%) (CesiumDiatriozate, 1).

To 24 mL of HEMA (200 mmol) in 1,000 mL of dry ether was added 16.8 mL(213 mmol) of pyridine at 4-10° C., under Ar. To this solution was added21.3 mL (200 mmol) of 1-chloroethyl chlorocarbonate, drop wise withstirring over 0.5 hr. After stirring 0.5 hr at 4-10° C., the heavyprecipitate was removed by filtration and the filtrate was concentratedto oil in vacuo, yielding 44 g (100%) (HEMA-1-Chloroethyl carbonate, 2).

To 44 g (200 mmol) of (2) in 400 mL of anhydrous DMF was added 30 g (40mmol) of (1) at 100° C. under Ar, with good stirring. After 15 minanother 40 g (54 mmol) of (1) was added at 100° C., under Ar, with goodstirring followed by a final 30 g (40 mmol), under the same conditions,for a total of 110 g (1) (134 mmol). The reddish brown reaction mixturewas heated at 100° C. for an additional hour and the solvent was removedin vacuo. The reddish brown solid residue was suspended in 1,000 mL ofdry ether and the solids collected on a Buchner funnel. After the solidswere dried in vacuo, they were suspended in 500 mL distilled water at2,000 rpm and the mixture pH was adjusted to 8-9 with cesium carbonate.After stirring for 10 min, the suspension was filtered and the solidswashed 3 times with 100 mL of distilled water, dried overnight in vacuoand crushed to a fine powder. Solid residue was again suspended in 1,000mL of dry ether and the solids were collected on a Buchner funnel. Afterthe solids were dried in vacuo again and crushed to a fine powder again,they were purified by silica gel chromatograph using a 1.5 Kg column anda 0-10% gradient of methanol in dichloromethane, over 1 hr. This yielded26 grams (18%), very pale yellow crystalline solid(1-((2-(methacryloyloxy)ethoxy)carbonyloxy)ethyl-3,5-diacetamido-2,4,6-triiodobenzoate,3).

EXAMPLE 9 Preparation of a Non-Degradable Radiopaque Monomer

Diatriazoyl Acetate (A): To 30.8 g of diatrizoic acid suspended in 100mL of acetic anhydride was added 2 g of concentrated sulfuric acid andthe resulting suspension stirred at 90 degrees centigrade for one hourbefore the reaction mixture was cooled to room temperature and thenpoured onto 500 g of ice. After agitating the ice for 15 min, the oilymass was treated with 100 mL of half saturated sodium bicarbonate whilstagitating. The solids which had formed were collected on a Buchnerfunnel and dried overnight in vacuo to give 9 g of light browndiatriazoyl acetate solids.

Diatriazoyl Chloride (B): Nine grams of ditriazoyl acetate was suspendedin 100 mL of thionyl chloride using overhead stirring. The reactionmixture was brought to reflux in an oil bath and refluxed for one hour.The thionyl chloride was mostly removed in vacuo at 40° C. at whichpoint solids were re-suspended in 100 mL of ethyl acetate which wasremoved in vacuo. This process was repeated twice more at which pointthe solids were placed under vacuum overnight.

Ethylenediamine mono-diatriazoyl amide (C): 6.3 g of the acid chloride(10 mmol) in 300 mL of methylene chloride was added to 6.7 grams ofethylene diamine (100 mmol) over one hour with stirring at 4-10° C.under Ar. The formed solids were collected on a Buchner funnel andwashed with 100 mL of methylene chloride and dried overnight in vacuo.The dried solids now largely free of ethylenediamine were taken up in600 mL of water filtered through a fritted disk funnel and the waterremoved in vacuo. The residue was triturated with acetonitrile which wasthen evaporated in vacuo to remove traces of water. LC-MS showed 640which is (M+Na)⁺ and 656.9, (M+K)⁺.

Ethylene diamine-1-diatriazoylamide-2-methacrylamide (D): To 650 mg of(C) (1 mmol) suspended in 100 mL of THF/CHCl₃/ethanol, 1/3/1 was added0.18 mL (1.04 mmol) of diisopropylethylamine followed by 0.12 mL (1.26mmol) of methacryoyl chloride with stirring under Ar. The reactionmixture was stirred for 1 hr at which point reaction mixture wasfiltered with a fritted Buchner funnel.

TLC with 10% methanol in methylene chloride showed potential product insolids and filtrate. LC-MS of combined filtrate and solids after solventremoval in vacuo showed (M+H)⁺ at 725.0, (M+Na)⁺ at 747.0 as well as(M−H)⁻ at 723.0 and (M+Na−2H)⁻ at 744.9 all on an HPLC peak at 8.9 minin a 15 min run.

Unless otherwise indicated, all numbers expressing quantities ofingredients, properties such as molecular weight, reaction conditions,and so forth used in the specification and claims are to be understoodas being modified in all instances by the term “about.” Accordingly,unless indicated to the contrary, the numerical parameters set forth inthe specification and attached claims are approximations that may varydepending upon the desired properties sought to be obtained by thepresent invention. At the very least, and not as an attempt to limit theapplication of the doctrine of equivalents to the scope of the claims,each numerical parameter should at least be construed in light of thenumber of reported significant digits and by applying ordinary roundingtechniques. Notwithstanding that the numerical ranges and parameterssetting forth the broad scope of the invention are approximations, thenumerical values set forth in the specific examples are reported asprecisely as possible. Any numerical value, however, inherently containscertain errors necessarily resulting from the standard deviation foundin their respective testing measurements.

The terms “a,” “an,” “the” and similar referents used in the context ofdescribing the invention (especially in the context of the followingclaims) are to be construed to cover both the singular and the plural,unless otherwise indicated herein or clearly contradicted by context.Recitation of ranges of values herein is merely intended to serve as ashorthand method of referring individually to each separate valuefalling within the range. Unless otherwise indicated herein, eachindividual value is incorporated into the specification as if it wereindividually recited herein. All methods described herein can beperformed in any suitable order unless otherwise indicated herein orotherwise clearly contradicted by context. The use of any and allexamples, or exemplary language (e.g., “such as”) provided herein isintended merely to better illuminate the invention and does not pose alimitation on the scope of the invention otherwise claimed. No languagein the specification should be construed as indicating any non-claimedelement essential to the practice of the invention.

Groupings of alternative elements or embodiments of the inventiondisclosed herein are not to be construed as limitations. Each groupmember may be referred to and claimed individually or in any combinationwith other members of the group or other elements found herein. It isanticipated that one or more members of a group may be included in, ordeleted from, a group for reasons of convenience and/or patentability.When any such inclusion or deletion occurs, the specification is deemedto contain the group as modified thus fulfilling the written descriptionof all Markush groups used in the appended claims.

Certain embodiments of this invention are described herein, includingthe best mode known to the inventors for carrying out the invention. Ofcourse, variations on these described embodiments will become apparentto those of ordinary skill in the art upon reading the foregoingdescription. The inventor expects skilled artisans to employ suchvariations as appropriate, and the inventors intend for the invention tobe practiced otherwise than specifically described herein. Accordingly,this invention includes all modifications and equivalents of the subjectmatter recited in the claims appended hereto as permitted by applicablelaw. Moreover, any combination of the above-described elements in allpossible variations thereof is encompassed by the invention unlessotherwise indicated herein or otherwise clearly contradicted by context.

In closing, it is to be understood that the embodiments of the inventiondisclosed herein are illustrative of the principles of the presentinvention. Other modifications that may be employed are within the scopeof the invention. Thus, by way of example, but not of limitation,alternative configurations of the present invention may be utilized inaccordance with the teachings herein. Accordingly, the present inventionis not limited to that precisely as shown and described.

We claim:
 1. An embolic system including: a syringe, a vial, or a combination thereof; and embolic particles having an organic polymer backbone including a reaction product of a prepolymer solution including: a poly(ethylene glycol) diacrylamide macromer, a poly(ethylene glycol) diacrylate macromer, a poly(ethylene glycol) dimethacrylate macromer, a poly(ethylene glycol) dimethacrylamide macromer, or a combination thereof; and at least one monomer, wherein the embolic particles have a diameter between about 50 μm and about 1,500 μm.
 2. The embolic system of claim 1, wherein the diameter is between about 400 μm and about 1,500 μm.
 3. The embolic system of claim 1, wherein the at least one monomer includes ionic groups.
 4. The embolic system of claim 3, wherein the monomer containing ionic groups is sodium acrylate.
 5. The embolic system of claim 1, wherein the prepolymer solution further includes a crosslinker.
 6. The embolic system of claim 5, wherein the crosslinker is biodegradable.
 7. The embolic system of claim 6, wherein the crosslinker has a structure:

wherein each n is independently 1-20;

wherein d, e, and f are each independently 1-20; or


8. The embolic system of claim 1, wherein the embolic particles further include a visualization agent having a structure:


9. The embolic system of claim 1, further including a flow diverting stent formed of a material having a pore size.
 10. The embolic system of claim 9, wherein the pore size is less than the diameter of the embolic particles.
 11. A method of treatment, the method comprising: delivering embolic particles through a delivery device to a treatment site jailed by a flow diverting stent, wherein the embolic particles having an organic polymer backbone and are formed from a reaction product of a prepolymer solution including: a poly(ethylene glycol) diacrylamide macromer, a poly(ethylene glycol) diacrylate macromer, a poly(ethylene glycol) dimethacrylate macromer, a poly(ethylene glycol) dimethacrylamide macromer, or a combination thereof; and at least one monomer, wherein the embolic particles have a diameter between about 50 μm and about 1,500 μm.
 12. The method of claim 11, wherein the delivering includes flushing the catheter with a non-solvent.
 13. The method of claim 12, wherein the non-solvent is a mineral oil, hexane, or water.
 14. The method of claim 11, wherein the delivery device is a catheter or a microcatheter.
 15. The method of claim 11, wherein the flow diverting stent includes a material having a pore size that is less than the diameter of the embolic particles.
 16. The method of claim 11, wherein the at least one monomer includes ionic groups.
 17. The method of claim 11, wherein the prepolymer solution further includes a crosslinker.
 18. The method of claim 17, wherein the crosslinker is biodegradable.
 19. The method of claim 17, wherein the crosslinker has a structure:

wherein each n is independently 1-20;

wherein d, e, f, and g are each independently 1-20; or


20. The method of claim 11, wherein the embolic particles further include a visualization agent having a structure: 